Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs

Scandinavian Journal of Gastroenterology

Volumn 33, Issue 8, 1998, Pages 828-832

  Wojdemann M ^a   Wettergren, A ^b   Hartmann, B ^b   Holst, J J ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

Antral motility; Enterogastrone; Glucagon like peptides

Indexed keywords

GLUCAGON LIKE PEPTIDE; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HORMONAL REGULATION; HORMONE ACTION; HYPOGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; STOMACH ANTRUM; STOMACH MOTILITY; SWINE;

ANIMALS; GASTRIC EMPTYING; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HYPOGLYCEMIA; PEPTIDES; POSTPRANDIAL PERIOD; PYLORIC ANTRUM; SWINE;

EID: 0031693473     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365529850171486     Document Type: Article

References (26)

1. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-8.
2. Mojsov S, Heinrich G, Wilson IB, Ravazola M, Orci L, Habener JF. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986;261:11880-9.
3. Ørskov C, Holst JJ, Knuthsen S, Baldissera FGA, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not the pancreas. Endocrinology 1986;119:1467-75.
4. Buhl T, Thim L, Kofod H, Ørskov C, Harling H, Holst JJ. Naturally occurring products of proglucagon 111-160 in the porcine and small intestine. J Biol Chem 1988;263:8621-4.
5. Holst JJ. Enteroglucagon. Ann Rev Physiol 1997;59:257-71.
6. Wettergren A, Schjoldager BGT, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
7. Layer P, Holst JJ, Grandt D, Goebell H. Heal release of glucagon-like peptide-1: association with inhibition of gastric acid in humans. Dig Dis Sci 1993;40:1074-82.
8. Layer P, Franke A, Holst JJ, Grandt D, Goebell H. Glucagon-like peptide-1 inhibits pancreatic enzyme secretion in humans. Gastroenterology 1996:110:F1409.
9. Holst JJ, Ørskov C, Hartmann B, Deacon CF. Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. The insulinotropic gut hormone glucagon-like-peptide-1. Front Diabetes 1997;13:24-48.
10. Schmidt WE, Siegel EG, Creutzfeldt W. Effect of glucagon-like peptide-1 on insulin secretion. Diabetologia 1985;28:704-7.
11. Drucker DJ, Ehrlich P, Asa L, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like-peptide-2. Proc Natl Acad Sci USA 1996;93:7911-6.
12. Holst JJ, Wettergren A, Wøjdemann M, Poulsen SS, Ørskov C. Glucagon-like peptide-1 (GLP-1) an important enterogastrone acting via the central nervous system. Hepatogastroenterol 1995;42:1071.
13. Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. In: Methods in neurosciences. New York: Academic Press, Inc.; 1991.
14. Hilsted L, Holst JJ. On the accuracy of radioimmunological determination of somatostatin in plasma. Regul Pept 1982;4:13-31.
15. Bell GI, Sanchez-Pescador R, Layborn PJ, Najarian RC. Exon duplication and divergence in the human glucason gene. Nature 1983;304:368-71.
16. Hartmann B, Johnsen AH, Ørskov C, Holst JJ. Structure, analysis and secretion of human glucagon-like peptide-2 (GLP-2). Diabetes 1996;45: Suppl 2:300A.
17. Shimizu I, Hirota M, Oboshi C, Shima K. Effect of glucagon-like peptide-1 and 2 on glycogenolysis in cultured rat hepatocytes. Biomed Res 1986;7:431-6.
18. Irwin DM, Wong J. Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding glucagon-like peptide-2. Mol Endocrinol 1995;9:267-77.
19. Lund PK, Hoyt E, Simmons JG, Ulshen MH. Regulation of intestinal glucagon gene expression during adaptive growth of small intestine. Digestion 1993;54:371-2.
20. Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 1997;272:G662-8.
21. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol 1997;273:E77-84.
22. Bloom SR. Gut hormones in adaption. Gut 1987;28: Suppl 1:31-5.
23. Nauck MA, Niederreichholz U, Ettler U, Holst JJ, Ørskov C, Ritzel R, et al. Glucacon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273(5 Pt 1):E981-8.
24. Miller RE, Chernish SM. The response of gastrointestinal tract motility to glucagon. In: Picazo J, editor. Glucagon in gastroenterology and hepatology. Lancaster, UK: MTP Press; 1982. p. 37-54.
25. Wen J, Phillips SF, Sarr MG, Kost LJ, Holst JJ. PYY and GLP-1 contribute to feed-back inhibtion from the canine ileum and colon. Am J Physiol 1995;269:G945-52.
26. Flint A, Raben A, Holst JJ, Astrup A. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans [abstract]. Int J Obes 1997;21 Suppl 2:28.